Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Publication year range
1.
Arch. esp. urol. (Ed. impr.) ; 73(6): 541-545, jul.-ago. 2020. tab, graf
Article in Spanish | IBECS | ID: ibc-195929

ABSTRACT

OBJETIVO: Nuestro objetivo es analizar la calidad de la información disponible en YouTube acerca de la disfunción eréctil. MATERIAL Y MÉTODOS: Realizamos una búsqueda en YouTube usando los términos "Problemas de Erección" (PE), "Impotencia" (I) y "Disfunción Eréctil" (DE); incluimos los 60 primeros vídeos para cada uno de ellos. Dos urólogos revisaron de forma independiente los videos clasificándolos en "Basados en evidencia científica" (BEC) y "No basados en evidencia científica" (NBEC) según la bibliografía actual. Se describen y comparan el número de visitas, la duración, el tiempo publicado, la información médica y el origen de cada vídeo por grupos. RESULTADOS: Analizamos 147 videos tras eliminar los repetidos y no concordantes. El índice Kappa fue 0,89 (IC95% 0,82-0,96). El 37% se consideraron BEC y el 63% NBEC. La mediana de reproducciones en el grupo BEC fue 24.356 (rango 96-126.410) y 44.416 entre los NBEC (190-10.318.642), siendo esta diferencia estadísticamente significativa. La mediana de duración fue 254 segundos (46-984) y 228 segundos (23-2.880) respectivamente; la mediana de tiempo publicado fue de 42 meses en los BEC (16-103) y de 29 en los NBEC (11-134). El 83% de los vídeos BEC provenían de webs de salud y programas de televisión, mientras que el 58% de los NBEC procedían de blogs. Los vídeos BEC trataban más de fisiopatología, etiología, disfunción endotelial, diagnóstico y tratamiento frente a los NBEC (p < 0,001). CONCLUSIÓN: Del total de videos revisados, el 37% se consideraron BEC. Los videos NBEC se reprodujeron más veces que los BEC


OBJECTIVE: The objective of our study is to stablish the scientific quality of the available information in YouTube about erectile dysfunction (ED). MATERIAL AND METHODS: We searched on YouTube three terms ("Problemas de Erección" (PE), "Impotencia" (I) y "Disfunción Eréctil" (DE)). The sixteen first videos from each term were selected for the analysis. Two independent urologists reviewed all videos and classified all of them in scientific evidence-based (SEB) or not scientific evidence-based (NSEB) according to the current literature. In the subgroup analysis we compare: number of visits, duration, time of publication, source and type of information. RESULTS: After excluding the repeated links and non-concordant videos between both urologists, we analysed 147 videos. The Kappa statistic was 0.89 (95% CI 0.85-0.96). 37% were considered SEB and 63% were considered NSEB. The median of reproductions in the SEB group was 24.356 (96-126.410) and 44.416 for NSEB (190-10.318.642); this difference was statistically significant. The median duration was 254 seconds (46-984) for the SEB group and 228 seconds for the NSEB (23-2.880); the median time of publication was 42 (16-103) months for the SEB group and 29 (11- 134) months for the other one. 83% of SEB videos were published in health networks and television programs, while 58% of NSEB were published in user blogs. The SEB videos show more information about pathophysiology, aetiology, endothelial dysfunction, diagnosis and treatment than NSEB (p < 0.001). CONCLUSIONS: 37% of the videos were considered SEB. The NSEB videos were significantly more played than SEB group


Subject(s)
Humans , Male , Webcasts as Topic , Social Media , Information Dissemination , Video Recording , Erectile Dysfunction , Webcasts as Topic/statistics & numerical data , Social Media/statistics & numerical data
3.
Arch Esp Urol ; 73(6): 541-545, 2020 Jul.
Article in Spanish | MEDLINE | ID: mdl-32633249

ABSTRACT

OBJECTIVE: The objective of our study is to stablish the scientific quality of the available information in YouTube about erectile dysfunction (ED). MATERIAL AND METHODS: We searched on YouTube thrree terms ("Problemas de Erección" (PE), "Impotencia"(I) y "Disfunción Eréctil" (DE)). The sixteen first videos from each term were selected for the analysis. Two independent urologists reviewed all videos and classified all of them in scientific evidence-based (SEB) or not scientific evidence-based (NSEB) according to the current literature. In the subgroup analysis we compare: number of visits, duration, time of publication, source and type of information. RESULTS: After excluding the repeated links and non-concordant videos between both urologists, we analysed 147 videos. The Kappa statistic was 0.89 (95% CI0.85-0.96). 37% were considered SEB and 63% were considered NSEB. The median of reproductions in the SEB group was 24.356 (96-126.410) and 44.416 for NSEB (190-10.318.642); this difference was statistically significant. The median duration was 254 seconds(46-984) for the SEB group and 228 seconds for the NSEB (23-2.880); the median time of publication was 42 (16-103) months for the SEB group and 29 (11-134) months for the other one. 83% of SEB videos were published in health networks and television programs,while 58% of NSEB were published in user blogs. The SEB videos show more information about pathophysiology,aetiology, endothelial dysfunction, diagnosis and treatment than NSEB (p<0.001). CONCLUSIONS: 37% of the videos were consideredSEB. The NSEB videos were significantly more playedthan SEB group.


OBJETIVO: Nuestro objetivo es analizar la calidad de la información disponible en YouTube acerca de la disfunción eréctil.MATERIAL Y MÉTODOS: Realizamos una búsqueda en YouTube usando los términos "Problemas de Erección" (PE), "Impotencia" (I) y "Disfunción Eréctil" (DE); incluimos los 60 primeros vídeos para cada uno de ellos. Dos urólogos revisaron de forma independiente los videos clasificándolos en "Basados en evidenciacientífica" (BEC) y "No basados en evidencia científica" (NBEC) según la bibliografía actual. Se describen y comparan el número de visitas, la duración, el tiempo publicado, la información médica y el origen de cada vídeo por grupos. RESULTADOS: Analizamos 147 videos tras eliminar los repetidos y no concordantes. El índice Kappa fue 0,89 (IC95% 0,82-0,96). El 37% se consideraron BEC y el 63% NBEC. La mediana de reproducciones en el grupo BEC fue 24.356 (rango 96-126.410) y 44.416 entre los NBEC (190-10.318.642), siendo esta diferencia estadísticamente significativa. La mediana de duración fue 254 segundos (46-984) y 228 segundos(23-2.880) respectivamente; la mediana de tiempo publicado fue de 42 meses en los BEC (16-103) y de 29 en los NBEC (11-134). El 83% de los vídeos BEC provenían de webs de salud y programas de televisión,mientras que el 58% de los NBEC procedían de blogs.Los vídeos BEC trataban más de fisiopatología, etiología,disfunción endotelial, diagnóstico y tratamiento frente a los NBEC (p<0,001).CONCLUSIÓN: Del total de videos revisados, el 37% se consideraron BEC. Los videos NBEC se reprodujeron más veces que los BEC.


Subject(s)
Erectile Dysfunction , Social Media , Humans , Male , Video Recording
4.
Urol Int ; 104(3-4): 323-326, 2020.
Article in English | MEDLINE | ID: mdl-31914452

ABSTRACT

Nivolumab is a fully human immunoglobulin G4 programmed death-1 (PD-1) immune checkpoint inhibitor antibody that selectively blocks the interaction between PD-1, which is expressed on activated T cells, and its ligands PD-L1 and PD-L2, which are expressed on immune cells and tumour cells. Patients with severe renal dysfunction and haemodialysis are not enrolled in clinical trials. However, in daily clinical practice, we have patients with metastatic renal cell carcinoma (mRCC) and end-stage renal disease (ESRD). The scientific evidence about the efficacy and safety of nivolumab in these patients is scarce. We report three cases of mRCC patients with ESRD treated with second-line nivolumab therapy. They received both biweekly and monthly schemes. None of our patients showed grade 2-4 toxicities. Two patients achieved partial response and one progressive disease as best response. Our patients did not show increased toxicity by ESRD; also, two of the three patients had objectifiable clinical benefit. Nivolumab seems to be similarly safe for ESRD or dialysis patients as for patients without impaired kidney function (IKF). Dose adjustments might not be necessary. We suggest that patients on dialysis could be treated with nivolumab in the same way as populations without IKF.


Subject(s)
Antineoplastic Agents, Immunological/administration & dosage , Carcinoma, Renal Cell/drug therapy , Kidney Failure, Chronic/complications , Kidney Neoplasms/drug therapy , Nivolumab/administration & dosage , Renal Dialysis , Aged , Antineoplastic Agents, Immunological/adverse effects , Carcinoma, Renal Cell/secondary , Drug Administration Schedule , Humans , Kidney Neoplasms/pathology , Male , Middle Aged , Nivolumab/adverse effects , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...